MedTrace Logo

Effect of Riociguat on Bone Metabolism

NCT00855660 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2016-01-11

No results posted yet for this study

Summary

Investigation of the effect of Riociguat, administered as 2.5 mg IR-tablets TID over 14 days, on bone metabolism.

Conditions

  • Pharmacology, Clinical

Interventions

DRUG

Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg

Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.

DRUG

Placebo

Placebo administered as a single tablet, thrice daily, over 14 days.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2009-12-31
Completion
2010-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00855660 on ClinicalTrials.gov